2011
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study
Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, Velazquez EJ, Hua TA, Kelly RY, Zappe D, Hester A, Tuomilehto J, Östergren J, Ibsen H, Weber M, INVESTIGATORS F. Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study. Blood Pressure 2011, 21: 82-87. PMID: 21830844, DOI: 10.3109/08037051.2011.598699.Peer-Reviewed Original ResearchConceptsSystolic blood pressureBetter SBP controlPrevious antihypertensive medicationsSBP controlAntihypertensive medicationsBaseline predictorsTreatment groupsHigher baseline systolic blood pressureCalcium channel blocker useUncontrolled systolic blood pressureHigher systolic blood pressureBaseline systolic blood pressureMain baseline predictorsUse of thiazidesSystolic BP levelsHigher diastolic BPMultivariable regression modelsLogistic regression modelsACCOMPLISH trialAmlodipine armRandomization armBlocker useCardiovascular outcomesInsulin useSystolic hypertension
2004
Relationship between heart failure treatment and development of worsening renal function among hospitalized patients11Guest Editor for this manuscript was Peter M. Okin, MD, New York Hosptial-Cornell Medical Center, New York, NY.
Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Wang Y, Young JB, Krumholz HM. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients11Guest Editor for this manuscript was Peter M. Okin, MD, New York Hosptial-Cornell Medical Center, New York, NY. American Heart Journal 2004, 147: 331-338. PMID: 14760333, DOI: 10.1016/j.ahj.2003.08.012.Peer-Reviewed Original ResearchConceptsFluid intake/outputHeart failureIntake/outputRenal functionHigh riskCalcium channel blocker useHistory of HFAssociation of medicationLoop diuretic dosesPredictors of WRFElevated creatinine levelEnzyme inhibitor useHeart failure treatmentCase-control studyUse of CCBGreater fluid lossHigher hematocrit levelsUncontrolled hypertensionBlocker useDiuretic dosesCreatinine levelsInhibitor useAcute treatmentDiabetes mellitusIndependent predictors
1997
Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction.
Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997, 277: 115-21. PMID: 8990335, DOI: 10.1001/jama.277.2.115.Peer-Reviewed Original ResearchConceptsCalcium channel blockersCalcium channel blocker useAdverse outcomesChannel blockersBlocker useEligible patientsMyocardial infarctionRelative riskMortality rateAcute myocardial infarction survivorsBaseline risk variablesCardiac hospital readmissionsElderly AMI survivorsBeta-blocker therapyBeta-blocker usePredictors of survivalRisk of deathRetrospective cohort designAcute myocardial infarctionDemonstrable adverse effectsMyocardial infarction survivorsPrescription drug coverageMeasurable adverse outcomesBeta blockersElderly patientsAdverse Outcomes of Underuse of β-Blockers in Elderly Survivors of Acute Myocardial Infarction
Soumerai S, McLaughlin T, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse Outcomes of Underuse of β-Blockers in Elderly Survivors of Acute Myocardial Infarction. JAMA 1997, 277: 115-121. DOI: 10.1001/jama.1997.03540260029031.Peer-Reviewed Original ResearchCalcium channel blockersCalcium channel blocker useΒ-blockersAdverse outcomesChannel blockersBlocker useEligible patientsMyocardial infarctionRelative riskMortality rateAcute myocardial infarction survivorsBaseline risk variablesCardiac hospital readmissionsElderly AMI survivorsΒ-blocker therapyΒ-blocker usePredictors of survivalRisk of deathRetrospective cohort designAcute myocardial infarctionDemonstrable adverse effectsMyocardial infarction survivorsNew β-blockerPrescription drug coverageMeasurable adverse outcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply